Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Liabilities for 11 consecutive years, with $422.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 4.34% to $422.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $422.7 million through Dec 2025, down 4.34% year-over-year, with the annual reading at $422.7 million for FY2025, 4.34% down from the prior year.
  • Total Liabilities for Q4 2025 was $422.7 million at Cartesian Therapeutics, up from $408.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $454.6 million in Q3 2024, with the low at $45.7 million in Q3 2023.
  • Average Total Liabilities over 5 years is $257.2 million, with a median of $191.1 million recorded in 2021.
  • The sharpest move saw Total Liabilities crashed 54.19% in 2022, then soared 894.56% in 2024.
  • Over 5 years, Total Liabilities stood at $137.4 million in 2021, then tumbled by 47.54% to $72.1 million in 2022, then surged by 517.11% to $444.7 million in 2023, then fell by 0.64% to $441.8 million in 2024, then decreased by 4.34% to $422.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $422.7 million, $408.5 million, and $391.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.